Prelude Trust, Avlar BioVentures and the Novartis Venture fund havetogether invested L3 million ($4.2 million) in Iceni BioDiscovery, a Cambridge, UK-based firm which is developing a new way to treat insulin-dependent diabetes by producing human cells in the laboratory for transplantation.
Iceni says it has other products in the pipeline for the treatment of chronic diseases. The company was founded in April this year by three ex-Novartis employees: Tony Talbot, Simon Thompson and Barbara Pagg.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze